Immune drug shows promise for untreated lymphoma patients
Disease control
Terminated
This study tested the drug pembrolizumab in 9 people with untreated B-cell non-Hodgkin lymphoma (follicular or marginal zone lymphoma). The goal was to see if this immunotherapy could shrink tumors by helping the immune system attack cancer cells. The trial was stopped early, so …
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Apr 29, 2026 02:37 UTC